Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK

[1] Hex N(2012)Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs Diabet Med 29 855-862

[2] Bartlett C(2014)Liraglutide: a review of its use in adult patients with type 2 diabetes mellitus Drugs 74 2161-2174

[3] Wright D(2015)Evaluating the cost-effectiveness of GLP-1 receptor agonists for the treatment of type 2 diabetes in the UK Value Health 18 A606-938

[4] Taylor M(2013)The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m2 in Spain J Med Econ 16 926-585

[5] Varley D(2015)Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway J Med Econ 18 573-724

[6] Scott LJ(2014)Validation of the IMS CORE Diabetes Model Value Health 17 714-S26

[7] Ashley D(2004)The CORE Diabetes Model: projecting long-term clinical outcomes, costs and costeffectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making Curr Med Res Opin 20 S5-S40

[8] Vega G(2004)Validation of the CORE Diabetes Model against epidemiological and clinical studies Curr Med Res Opin 20 S27-1456

[9] Hunt B(2014)Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled type 2 diabetes on oral antidiabetic drugs in Greece BMC Health Serv Res 14 1-1230

[10] Valentine WJ(2010)Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial Lancet 375 1447-1759

[1] Hex N(2012)Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs Diabet Med 29 855-862

[2] Bartlett C(2014)Liraglutide: a review of its use in adult patients with type 2 diabetes mellitus Drugs 74 2161-2174

[3] Wright D(2015)Evaluating the cost-effectiveness of GLP-1 receptor agonists for the treatment of type 2 diabetes in the UK Value Health 18 A606-938

[4] Taylor M(2013)The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m2 in Spain J Med Econ 16 926-585

[5] Varley D(2015)Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway J Med Econ 18 573-724

[6] Scott LJ(2014)Validation of the IMS CORE Diabetes Model Value Health 17 714-S26

[7] Ashley D(2004)The CORE Diabetes Model: projecting long-term clinical outcomes, costs and costeffectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making Curr Med Res Opin 20 S5-S40

[8] Vega G(2004)Validation of the CORE Diabetes Model against epidemiological and clinical studies Curr Med Res Opin 20 S27-1456

[9] Hunt B(2014)Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled type 2 diabetes on oral antidiabetic drugs in Greece BMC Health Serv Res 14 1-1230

[10] Valentine WJ(2010)Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial Lancet 375 1447-1759